Gilead (Shanghai) Pharmaceutical Technology Co
Gilead (Shanghai) Pharmaceutical Technology Co was established on March 21, 2017 in Lujiazui, East China's Shanghai. As the regional headquarters of Gilead Sciences, the company is involved in the research and development of drugs. It also provides technology services and consulting.
Established in 1987, Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.
Over the past three decades, the company has made significant breakthroughs in developing HIV and hepatitis C medications. For example, its drug sofosbuvir, which was approved by the US Food and Drug Administration in 2013, is the world's first cure for hepatitis C.
Gilead has been continuously expanding its business by acquiring 15 leading pharmaceutical companies, such as Kite Pharma. To date, it has launched more than 25 innovative medicines in the market that treat a variety of diseases including HIV, hepatitis, and respiratory diseases.
Starting from 2007, Gilead has been growing and thriving in the Chinese market, turning itself from a drug maker to an industry leader. The company's team in China now has more than 300 people in 40 cities across the country.
In addition, it has introduced eight innovative medicines into China. In August 2020, its pre-exposure prophylaxis drug, which helps prevent people at risk of HIV from getting infected through sex or injection drug use, was approved by China's National Medical Products Administration. It is the only medicine of its kind that is approved in China.